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ABSTRACT  Objective: To study influence of cinepazide maleate on vascular 
endothelial function of patients with acute myocardial infarction. Methods: 
150 cases of patients with acute myocardial infarction were divided into 
the observation group and the control group, two groups were treated by 
conventional therapy about acute myocardial infarction, the observation group 
added 5%GS250 mL + cinepazide maleate 160 mg IV drip q.d, the control group 
added 5%GS250 mL IV drip q.d, the treatment course were 3 weeks, changes 
of vascular endothelial function and the blood serum no level before and after 
treatment were detected. Result: vascular endothelial function after treatment in 
observation group were obviously improved than that before treatment (ρ  = 0.03) 
, blood serum no level was obviously increased (ρ  ﹤ 0.05); about 3 weeks after 
treatment, vascular endothelial function in the observation group was obviously 
better than that of the control group (ρ  = 0.04), the blood serum no level of the 
observation group was obviously higher than that of the control group (ρ  ﹤ 0.05). 
Conclusion: Cinepazide maleate remarkably improves vascular endothelial 
function of patients with acute myocardial infarction. 
 ORIGINAL ARTICLE
1. Introduction
Cinepazide maleate is a novel substituted piperazines, has 
a variety of pharmacological effects such as endogenous 
adenosine to improve efficiency, calcium channel blockers, 
phosphodiesterase inhibition, etc. There are more clinical 
study on vasorelaxation action while less reports on effect 
of vascular endothelial function. In this paper, intravenous 
infusion of cinepazide maleate was administrated to patients
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with acute myocardial infarction by the randomized, 
control design method, to observe the changes of 
endothelial function.
2. Materials and methods
2.1. Study subjects
150 patients with acute myocardial infarction treated in our 
hospital from March 2010 to December 2011 were selected 
as the study subjects. Inclusion criteria: (1) meet the 
diagnostic criteria of acute myocardial infarction [1–2]; (2) 
any vascular disease has not occurred; (3) excluding liver, 
gallbladder, pancreas, thyroid and kidney disorders; (4) 
have regular eating habits and a certain amount of activity; 
(5) non-diabetic patients; (6) hypertension. 150 patients 
were randomly divided into two groups, the observation 
group was 78 cases and the control group was 72 cases. 
The control group and observation group were roughly 
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matched in age, gender, smoking, taking drugs, alcohol 
consumption, and body mass index, etc.
   General information of the subjects (Table 1) displays there 
was no significant difference in gender, age, smoking, taking 
drugs, alcohol consumption, and body mass index and so on.
Table 1. General information.
The observation group The control group
Case(male/female) 78 (40/38) 72 (37/35)












Β receptor blocker 21 23
2.2. Methods
On the basis of routine treatment of myocardial infarction, the 
observation group added 5%GS250 mL + Cinepazide maleate 
160 mg IV drip q.d, the control group added 5%GS250 mL iv 
drip q.d, the treatment course were 3 weeks.
2.3. Specimen collection and testing
Three mL elbow venous blood was taken from all the 
subjects after  fasting for 12 hours in the morning of 
selection and 3 weeks after treatment. Immediately 
centrifuge for 25 minutes with high speed at room 
temperature (3000 rpm/min ), separated serum was stored 
in the refrigerator under –70 °C to be measured, uniform 
determination of NO in serum was made.
2.4. Determination of vascular endothelial function
Non-invasive detection of vascular endothelial function 
is made before and 3 weeks after treatment respectively. 
Determination of vascular endothelial function: use the 
hpsonos 5500 color doppler ultrasound system (Hewlett-
Packard Development Company), transducer frequency is 
10 mhz, synchronously record the ECG. The subjects take 
a break for 10 min before testing, stay in supine position, 
right upper arm outreach for 15 degrees. Selected 2~15 
cm range of brachial artery in the cubital fossa as the 
target artery, 4 cm depth, freeze after getting satisfactory 
long axis image of the brachial artery. At the top of the R 
wave in ECG, measure ventricular end-diastolic diameter 
of brachial artery, take the average of 3 cycles as a basis 
inner diameter of brachial artery (D0), mark on the 
skin of the test location for repeated operations. Bind 
cuff blood pressure monitor to the right forearm and 
inflate until blood pressure monitor readings reach to 
300 mmHg, maintain for 5 min, quickly deflate, measure 
ventricular end-diastolic diameter of brachial artery (D1) 
of original marked position again within 90 s. The patient 
rest for more than 10 min, give sublingual nitroglycerin 
0.5 mg , 5 min later the brachial artery diameter (D2) is 
measured. Consider the brachial artery diameter change 
percentages before and after reactive hyperemia and taking 
nitroglycerin as endothelium-dependent vasodilation 
(Flow-mediated dilation, FMD) and non-endothelial 
dependent relaxation (endothelium-independent 
dilatation, EID). Calculated as: FMD = (D1 − D0) / D0 
×100%; EID = (D2 − D0) / D0 ×100%.
2.5. Statistics analysis
Using the SPSS 11.0 statistical software for statistical 
analysis: measurement data is represented as (x ± s); 
comparison between groups and within group is made 
by t  test and analysis of variance, respectively; p < 0.05 is 
considered to be statistically significant difference.
3. Results
3.1. the FMD, EID changes of brachial artery in each 
group before and after 3 weeks ( see table 2 ).
Table 2. The FMD, EID changes of brachial artery in each group 
before and after 3 weeks.
The control group the observation group
3 weeks ago after 3 weeks 3 weeks ago after 3 weeks
FMD (%) 8.9 ± 0.4 9.9 ± 1.4 9.0 ± 0.4 14.1 ± 1.2 *
EID (%) 14.6 ± 4.5 18.5 ± 5.9 17.7 ± 4.2 18.5 ± 4.0
FMD: flow- mediated vasodilation, EID: nitroglycerin- mediated 
vasodilation
*: comparison of before and after 3 weeks, the observation group FMD 
improved significantly (p = 0.03); 3 weeks after treatment, the FMD of 
observation group improved more significantly than the control group 
(p = 0.04);
3.2. Serum NO changes of each group before and after 
3 weeks 
Serum NO changes: serum NO level in observation group 
and control group has no significant difference 3 weeks 
ago; after 3 weeks, the serum NO level of observation 
group increases significantly (p < 0.05) while the control 
group has no significant difference, the serum NO level of 
observation group is significantly higher than the control 
group (p < 0.05) (Table 3).
Table 3. Serum NO changes of each group before and after 3 
weeks.
The control group The observation group
NO 
(μ mol/l)
3 weeks ago After 3 weeks 3 weeks ago After 3 weeks
41.0 ± 5.1 42.3± 4.3 39.2 ± 3.8 61.0 ± 7.5*
NO: nitric oxide
*means the significant change in serum NO of observe group 3 weeks 
later compared with 3 weeks ago (p ﹤ 0.05); means serum NO level in 
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observation group is significantly higher than the control group after 
3 weeks (p ﹤ 0.05);
3. Discussion 
Cinepazide maleate is a novel substituted piperazines, has 
a variety of pharmacological effects such as endogenous 
adenosine to improve efficiency, calcium channel blockers, 
phosphodiesterase inhibition, etc. [3]. Cinepazide maleate 
has weak inhibitory effect of calcium ion, it also has good 
spasmolysis and expansion on coronary artery, cerebral 
arteries and peripheral vessels [4]. Cinepazide has a unique 
synergy of adenosine. It blocks adenosine inactivation 
process by blocking the reabsorption of adenosine and 
inhibition of adenosine deaminase activity, delay the 
metabolism of adenosine, thereby increasing the lesion 
local concentration of endogenous adenosine, regulating 
peripheral artery and coronary artery diastolic function [5]. 
Through using cinepazide maleate for 3 weeks on the basis 
of conventional therapy in patients with acute myocardial 
infarction, the study shows that cinepazide maleate has 
effect on improving vascular endothelial function, vascular 
active substance NO which associated with the vascular 
endothelial dilatation function is significantly increased. 
   Xiaoqiu zhou [6], Lijing zhao [6] and others have made 
a study on unstable angina application patients who using 
cinepazide maleate. The results shows application of 
cinepazide maleate injection on the conventional treatment 
in UAP treatment can obviously improve the clinical 
curative effect, clinical symptoms and exercise tolerance, 
reduce whole blood low shear viscosity, whole blood high 
shear viscosity, plasma viscosity, platelet aggregation, 
platelet adhesion rate, improve ECG manifestations, reduce 
acute myocardial infarction, arrhythmia and other severe 
cardiovascular complications. The study by Huapin wang, 
et al [8]found that use of cinepazide maleate combined 
with xuesaitong in the treatment of UAP has synergy 
in improving the hemorheology and atherosclerosis 
inflammatory reaction. Xiaohua Luo, et al [9] found 
that cinepazide maleate combined with irbesartan can 
effectively control blood pressure, obviously improve 
clinical symptoms and ECG curative effect of angina 
pectoris patients, reduce the frequency of angina attacks, 
improve myocardial ischemia and enhance heart function. 
Chengjun shi, et al [10] found combination of sodium 
tanshinone IIA sulfonate and cinepazide maleate in the 
treatment of angina pectoris of coronary heart disease can 
improve clinical syndrome and the electrocardiogram in 
patients with coronary heart disease. Musheng Yu, et al [11] 
shows that after intravenous infusion of cinepazide maleate, 
diabetic patients artery FMD improves significantly, 
indicating improving vascular endothelial function. The 
above study shows cinepazide maleate can significantly 
improves vasodilation function and adenosine synergies, 
expand blood vessels, has good spasmolysis and expansion 
on coronary artery, cerebral arteries and peripheral vessels, 
also can inhibit platelet aggregation, reduce the production 
of oxygen free radicals, reduce neutrophil chemotactic 
effects on vascular endothelial cells, increase the toughness 
and deformation capacity of cells and decrease blood 
viscosity, thereby improving the microcirculation 
perfusion. This study suggests that cinepazide maleate 
can significantly improve vascular endothelial function, 
increased endothelial-derived relaxing factor NO, it’s 
mechanism need further research.
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